JMJD

亜型選択性的な製品

JMJD製品

  • All (11)
  • JMJD阻害剤 (10)
  • 新製品
製品コード 製品名称 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
S7070 GSK J4 HCl GSK J4 HCl is a cell permeable prodrug of GSK J1, which is the first selective inhibitor of the H3K27 histone demethylase JMJD3 and UTX with IC50 of 60 nM in a cell-free assay and inactive against a panel of demethylases of the JMJ family.
Mol Cell, 2025, 85(15):2973-2987.e6
Nat Cell Biol, 2024, 26(7):1165-1175
J Clin Invest, 2024, 134(24)e173403
GSK-J4-HCl-S707001Z0620161101.gif
S8287 CPI-455 HCl CPI-455 HCl is a specific KDM5 inhibitor, elevating global levels of H3K4 trimethylation (H3K4me3) and decreased the number of DTPs in multiple cancer cell line models treated with standard chemotherapy or targeted agents.
Nature, 2023, 622(7983):619-626
Nature, 2023, 622(7983):619-626
Cancer Cell, 2023, 41(6):1118-1133.e12
S7281 JIB-04 JIB-04 (NSC 693627) is a pan-selective Jumonji histone demethylase inhibitor with IC50 of 230, 340, 855, 445, 435, 1100, and 290 nM for JARID1A, JMJD2E, JMJD3, JMJD2A, JMJD2B, JMJD2C, and JMJD2D in cell-free assays, respectively. JIB‑04 also induces cell apoptosis.
Mol Cell, 2025, 85(15):2973-2987.e6
J Immunother Cancer, 2025, 13(10)e013269
Front Cell Dev Biol, 2025, 13:1566567
JIB-04-S728101W0320161124.gif
S7296 ML324 ML324 is a selective inhibitor of jumonji histone demethylase (JMJD2) with IC50 of 920 nM.
Mol Cell, 2025, 85(15):2973-2987.e6
Cancer Cell, 2023, 41(6):1118-1133.e12
EBioMedicine, 2023, 92:104602
S7234 IOX1 IOX1 is a potent and broad-spectrum inhibitor of 2OG oxygenases, including the JmjC demethylases. IOX1 is an inhibitor of ALKBH5.
Mol Cell, 2025, 85(15):2973-2987.e6
Cancer Gene Ther, 2025, 10.1038/s41417-025-00874-z
Front Immunol, 2024, 15:1308978
S7581 GSK J1 GSK-J1 is a highly potent H3K27 histone demethylase inhibitor with IC50 of 28 nM and 53 nM in cell-free assays for JMJD3 (KDM6B) and UTX (KDM6A), respectively, >10-fold selectivity over other tested demethylases.
Cancer Gene Ther, 2025, 10.1038/s41417-025-00874-z
Commun Biol, 2025, 8(1):269
Chem Biol Interact, 2025, 418:111576
S8601 CP2 CP2 is a cyclic peptide that inhibits the JmjC histone demethylases KDM4 with IC50 values of 42 nM and 29 nM for KDM4A and KDM4C, respectively.
Clin Mol Hepatol, 2025, 10.3350/cmh.2024.0694
Oxid Med Cell Longev, 2022, 2022:2405943
Front Cell Dev Biol, 2021, 9:697614
E1315 iJMJD6 iJMJD6(WL12) is an inhibitor of arginine demethylase JMJD6 with an IC50 value of 0.22 μM.
F1232 JARID2 Antibody [N13E9]
S0201 Z-JIB-04 (NSC 693627) Z-JIB-04 (NSC 693627, JIB-04 Z-isomer) is an isomer of JIB-04. JIB-04 is a pan-selective Jumonji histone demethylase inihibitor with IC50 of 230 nM, 340 nM, 855 nM, 445 nM, 435 nM, 1100 nM and 290 nM for JARID1A, JMJD2E, JMJD3, JMJD2A, JMJD2B, JMJD2C, and JMJD2D, respectively.
Mol Cell, 2025, 85(15):2973-2987.e6
Cell Death Discov, 2025, 11(1):326
S4800New Daminozide Daminozide (Aminozide, DMASA, DIMG, B 995, Alar, Kylar, B-NINE, SADH) is a plant growth regulator that selectively inhibits human KDM2/7 histone demethylases, with IC50 of 0.55 μM for PHF8 (KDM7B), 1.5 μM for KDM2A, and 2.1 μM for KIAA1718 (KDM7A). It shows over 100-fold selectivity for the KDM2/7 subfamily compared to other histone demethylase subfamilies, with significantly weaker activity against enzymes such as KDM3A with IC50 of 127 μM.
S7070 GSK J4 HCl GSK J4 HCl is a cell permeable prodrug of GSK J1, which is the first selective inhibitor of the H3K27 histone demethylase JMJD3 and UTX with IC50 of 60 nM in a cell-free assay and inactive against a panel of demethylases of the JMJ family.
Mol Cell, 2025, 85(15):2973-2987.e6
Nat Cell Biol, 2024, 26(7):1165-1175
J Clin Invest, 2024, 134(24)e173403
GSK-J4-HCl-S707001Z0620161101.gif
S8287 CPI-455 HCl CPI-455 HCl is a specific KDM5 inhibitor, elevating global levels of H3K4 trimethylation (H3K4me3) and decreased the number of DTPs in multiple cancer cell line models treated with standard chemotherapy or targeted agents.
Nature, 2023, 622(7983):619-626
Nature, 2023, 622(7983):619-626
Cancer Cell, 2023, 41(6):1118-1133.e12
S7281 JIB-04 JIB-04 (NSC 693627) is a pan-selective Jumonji histone demethylase inhibitor with IC50 of 230, 340, 855, 445, 435, 1100, and 290 nM for JARID1A, JMJD2E, JMJD3, JMJD2A, JMJD2B, JMJD2C, and JMJD2D in cell-free assays, respectively. JIB‑04 also induces cell apoptosis.
Mol Cell, 2025, 85(15):2973-2987.e6
J Immunother Cancer, 2025, 13(10)e013269
Front Cell Dev Biol, 2025, 13:1566567
JIB-04-S728101W0320161124.gif
S7296 ML324 ML324 is a selective inhibitor of jumonji histone demethylase (JMJD2) with IC50 of 920 nM.
Mol Cell, 2025, 85(15):2973-2987.e6
Cancer Cell, 2023, 41(6):1118-1133.e12
EBioMedicine, 2023, 92:104602
S7234 IOX1 IOX1 is a potent and broad-spectrum inhibitor of 2OG oxygenases, including the JmjC demethylases. IOX1 is an inhibitor of ALKBH5.
Mol Cell, 2025, 85(15):2973-2987.e6
Cancer Gene Ther, 2025, 10.1038/s41417-025-00874-z
Front Immunol, 2024, 15:1308978
S7581 GSK J1 GSK-J1 is a highly potent H3K27 histone demethylase inhibitor with IC50 of 28 nM and 53 nM in cell-free assays for JMJD3 (KDM6B) and UTX (KDM6A), respectively, >10-fold selectivity over other tested demethylases.
Cancer Gene Ther, 2025, 10.1038/s41417-025-00874-z
Commun Biol, 2025, 8(1):269
Chem Biol Interact, 2025, 418:111576
S8601 CP2 CP2 is a cyclic peptide that inhibits the JmjC histone demethylases KDM4 with IC50 values of 42 nM and 29 nM for KDM4A and KDM4C, respectively.
Clin Mol Hepatol, 2025, 10.3350/cmh.2024.0694
Oxid Med Cell Longev, 2022, 2022:2405943
Front Cell Dev Biol, 2021, 9:697614
E1315 iJMJD6 iJMJD6(WL12) is an inhibitor of arginine demethylase JMJD6 with an IC50 value of 0.22 μM.
S0201 Z-JIB-04 (NSC 693627) Z-JIB-04 (NSC 693627, JIB-04 Z-isomer) is an isomer of JIB-04. JIB-04 is a pan-selective Jumonji histone demethylase inihibitor with IC50 of 230 nM, 340 nM, 855 nM, 445 nM, 435 nM, 1100 nM and 290 nM for JARID1A, JMJD2E, JMJD3, JMJD2A, JMJD2B, JMJD2C, and JMJD2D, respectively.
Mol Cell, 2025, 85(15):2973-2987.e6
Cell Death Discov, 2025, 11(1):326
S4800New Daminozide Daminozide (Aminozide, DMASA, DIMG, B 995, Alar, Kylar, B-NINE, SADH) is a plant growth regulator that selectively inhibits human KDM2/7 histone demethylases, with IC50 of 0.55 μM for PHF8 (KDM7B), 1.5 μM for KDM2A, and 2.1 μM for KIAA1718 (KDM7A). It shows over 100-fold selectivity for the KDM2/7 subfamily compared to other histone demethylase subfamilies, with significantly weaker activity against enzymes such as KDM3A with IC50 of 127 μM.
S4800New Daminozide Daminozide (Aminozide, DMASA, DIMG, B 995, Alar, Kylar, B-NINE, SADH) is a plant growth regulator that selectively inhibits human KDM2/7 histone demethylases, with IC50 of 0.55 μM for PHF8 (KDM7B), 1.5 μM for KDM2A, and 2.1 μM for KIAA1718 (KDM7A). It shows over 100-fold selectivity for the KDM2/7 subfamily compared to other histone demethylase subfamilies, with significantly weaker activity against enzymes such as KDM3A with IC50 of 127 μM.